scholarly journals The current status of pancreatic islet transplantation in Britain

2008 ◽  
Vol 25 (6) ◽  
pp. 218-220
Author(s):  
Martin Press
Keyword(s):  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Current Status ◽  
Pancreatic Islet Transplantation

Current status of pancreatic islet transplantation

2006 ◽  
Vol 110 (6) ◽  
pp. 611-625 ◽  
Author(s):  
Shaheed Merani ◽  
A. M. James Shapiro
Keyword(s):  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Current Status ◽  
Small Subset ◽  
Type I ◽  
Pancreatic Islet Transplantation ◽  
Post Transplantation ◽  
Edmonton Protocol ◽  
Islet Transplants ◽  
Islet Survival

DM (diabetes mellitus) is a metabolic disorder of either absolute or relative insulin deficiency. Optimized insulin injections remain the mainstay life-sustaining therapy for patients with T1DM (Type I DM) in 2006; however, a small subset of patients with T1DM (approx. 10%) are exquisitely sensitive to insulin and lack counter-regulatory measures, putting them at higher risk of neuroglycopenia. One alternative strategy to injected insulin therapy is pancreatic islet transplantation. Islet transplantation came of age when Paul E. Lacy successfully reversed chemical diabetes in rodent models in 1972. In a landmark study published in 2000, Shapiro et al. [A. M. Shapiro, J. R. Lakey, E. A. Ryan, G. S. Korbutt, E. Toth, G. L. Warnock, N. M. Kneteman and R. V. Rajotte (2000) N. Engl. J. Med. 343, 230–238] reported seven consecutive patients treated with islet transplants under the Edmonton protocol, all of whom maintained insulin independence out to 1 year. Substantial progress has occurred in aspects of pancreas procurement, transportation (using the oxygenated two-layer method) and in islet isolation (with controlled enzymatic perfusion and subsequent digestion in the Ricordi chamber). Clinical protocols to optimize islet survival and function post-transplantation improved dramatically with the introduction of the Edmonton protocol, but it is clear that this approach still has potential limitations. Newer pharmacotherapies and interventions designed to promote islet survival, prevent apoptosis, to promote islet growth and to protect islets in the long run from immunological injury are rapidly approaching clinical trials, and it seems likely that clinical outcomes of islet transplantation will continue to improve at the current exponential pace.

A subcutaneous pancreatic islet transplantation platform using a clinically applicable, biodegradable Vicryl mesh scaffold ‐ an experimental study

2020 ◽  
Vol 33 (7) ◽  
pp. 806-818 ◽  
Author(s):  
Hirotake Komatsu ◽  
Nelson Gonzalez ◽  
Mayra Salgado ◽  
Colin A. Cook ◽  
Junfeng Li ◽  
...  
Keyword(s):  
Experimental Study ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Pancreatic Islet Transplantation ◽  
Vicryl Mesh

scholarly journals Tolerance and pancreatic islet transplantation

2001 ◽  
Vol 356 (1409) ◽  
pp. 759-765 ◽  
Author(s):  
Luca Inverardi ◽  
Camillo Ricordi
Keyword(s):  
Diabetes Mellitus ◽  
Islet Transplantation ◽  
Type I Diabetes ◽  
Immunological Tolerance ◽  
Type I Diabetes Mellitus ◽  
Current Status ◽  
Type I ◽  
Pancreatic Islet Transplantation ◽  
Term Survival

Islet transplantation holds renewed promise as a cure for type I diabetes mellitus. Results of recent clinical trials have shown remarkable success, and have reignited universal optimism for this procedure. In spite of this success, the need for life–long immunosuppression of the recipient still limits islet transplantation to patients with poorly controlled diabetes or to those requiring kidney transplantation. It is obvious that the achievement of immunological tolerance would broaden the indication for islet transplantation to a much larger cohort of patients with type I diabetes mellitus, most likely preventing long–term complications and contributing to a much improved quality of life. Increased understanding of the basic mechanisms of tolerance induction has resulted in the implementation of numerous experimental approaches to achieve long–term survival of islet grafts in the absence of chronic immunosuppression. In this brief review we will attempt to summarize the current status of research and knowledge.

scholarly journals Current state and future evolution of pancreatic islet transplantation

2018 ◽  
Vol 3 (1) ◽  
pp. 34-42 ◽  
Author(s):  
Takayuki Anazawa ◽  
Hideaki Okajima ◽  
Toshihiko Masui ◽  
Shinji Uemoto
Keyword(s):  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Pancreatic Islet Transplantation ◽  
Future Evolution ◽  
Current State

scholarly journals The Long Road to Pancreatic Islet Transplantation

2009 ◽  
Vol 34 (4) ◽  
pp. 625-627 ◽  
Author(s):  
Mark A. Hardy ◽  
Piotr Witkowski ◽  
Hugo Sondermeijer ◽  
Paul Harris
Keyword(s):  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Pancreatic Islet Transplantation
Sign in / Sign up

Export Citation Format

Share Document